StemXBio is a biotech startup creating 3D pancreatic microtissues from iPSCs using a chemically defined, animal‑free differentiation protocol for diabetes drug discovery. Supplied in standard high‑throughput plate formats and containing all key pancreatic cell types, its models aim to lower clinical trial failure rates before expanding to other endodermal tissues.